The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence.
Biomarkers
Coagulation
Endothelial
Inflammation
Platelets
Rivaroxaban
Thrombin
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
accepted:
15
01
2023
medline:
19
4
2023
pubmed:
7
2
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
Rivaroxaban is a direct, oral factor Xa inhibitor that is used for the prevention and treatment of various thromboembolic disorders. Several preclinical and clinical studies have utilized specific molecules as biomarkers to investigate the potential role of rivaroxaban beyond its anticoagulant activity and across a range of biological processes. The aim of this review is to summarize the existing evidence regarding the use of blood-based biomarkers to characterize the effects of rivaroxaban on coagulation and other pathways, including platelet activation, inflammation and endothelial effects. After a literature search using PubMed, almost 100 preclinical and clinical studies were identified that investigated the effects of rivaroxaban using molecular biomarkers. In agreement with the preclinical data, clinical studies reported a trend for reduction in the blood concentrations of D-dimers, thrombin-antithrombin complex and prothrombin fragment 1 + 2 following treatment with rivaroxaban in both healthy individuals and those with various chronic conditions. Preclinical and also some clinical studies have also reported a potential impact of rivaroxaban on the concentrations of platelet activation biomarkers (von Willebrand factor, P-selectin and thrombomodulin), endothelial activation biomarkers (matrix metalloproteinase-9, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1) and inflammation biomarkers (interleukin-6, tumor necrosis factor-α and monocyte chemoattractant protein-1). Based on the results of biomarker studies, molecular biomarkers can be used in addition to traditional coagulation assays to increase the understanding of the anticoagulation effects of rivaroxaban. Moreover, there is preliminary evidence to suggest that rivaroxaban may have an impact on the biological pathways of platelet activation, endothelial activation and inflammation; however, owing to paucity of clinical data to investigate the trends reported in preclinical studies, further investigation is required to clarify these observations.
Identifiants
pubmed: 36746885
doi: 10.1007/s11239-023-02776-z
pii: 10.1007/s11239-023-02776-z
pmc: PMC10110699
doi:
Substances chimiques
Rivaroxaban
9NDF7JZ4M3
Factor Xa Inhibitors
0
Biomarkers
0
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
449-463Informations de copyright
© 2023. The Author(s).
Références
Rasche H (2001) Haemostasis and thrombosis: an overview. Eur Heart J Suppl. 3((suppl_Q)):Q3-7
doi: 10.1016/S1520-765X(01)90034-3
Fisher WD (2011) Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Can J Surg 54(5):344–351
pubmed: 21774881
pmcid: 3195664
doi: 10.1503/cjs.007310
Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: virchow’s triad revisited. Lancet 373(9658):155–166
pubmed: 19135613
doi: 10.1016/S0140-6736(09)60040-4
Pop C, Matei C, Petris A (2019) Anticoagulation in acute coronary syndrome: review of major therapeutic advances. Am J Ther 26(2):e184–e197
pubmed: 30839367
doi: 10.1097/MJT.0000000000000913
Thomas DP, Roberts HR (1997) Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 126(8):638–644
pubmed: 9103132
doi: 10.7326/0003-4819-126-8-199704150-00009
Kubitza D et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873–880
pubmed: 16328318
doi: 10.1007/s00228-005-0043-5
Palta S, Saroa R, Palta A (2014) Overview of the coagulation system. Indian J Anaesth 58(5):515–523
pubmed: 25535411
pmcid: 4260295
doi: 10.4103/0019-5049.144643
FDA-NIH Biomarker Working Group, BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016. https://www.ncbi.nlm.nih.gov/books/NBK326791/?report=classic . Accessed 11 Feb 2019.
Eikelboom JW et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330
pubmed: 28844192
doi: 10.1056/NEJMoa1709118
Borst O et al (2018) Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Adv 2(6):715–730
pubmed: 29588304
pmcid: 5873232
doi: 10.1182/bloodadvances.2017013573
Göbel K et al (2018) The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders—a systematic review. Front Immunol. https://doi.org/10.3389/fimmu.2018.01731
doi: 10.3389/fimmu.2018.01731
pubmed: 30105021
pmcid: 6077258
Esmon CT (2014) Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 111(4):625–633
pubmed: 24336942
doi: 10.1160/TH13-09-0730
Bai JPF et al (2011) Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J 13(2):274–283
pubmed: 21448748
pmcid: 3085704
doi: 10.1208/s12248-011-9265-x
Samama MM (2011) The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor–compared with other anticoagulants. Thromb Res 127(6):497–504
pubmed: 20888031
doi: 10.1016/j.thromres.2010.09.008
Perzborn E et al (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 30(3):376–381
pubmed: 20139357
doi: 10.1161/ATVBAHA.110.202978
Perzborn E et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514–521
pubmed: 15748242
doi: 10.1111/j.1538-7836.2005.01166.x
Arachchillage DR et al (2015) Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 135(2):388–393
pubmed: 25555316
doi: 10.1016/j.thromres.2014.11.037
Ebner M et al (2017) Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. Stroke 48(9):2457–2463
pubmed: 28775134
doi: 10.1161/STROKEAHA.117.017981
Gheorghiade M et al (2011) Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. J Heart Lung Transplant 30(2):218–226
pubmed: 20947383
doi: 10.1016/j.healun.2010.08.027
Graff J et al (2007) Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 47(11):1398–1407
pubmed: 17873238
doi: 10.1177/0091270007302952
Green L et al (2010) The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 151(5):469–476
pubmed: 20950405
doi: 10.1111/j.1365-2141.2010.08433.x
Hagii J et al (2016) Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: insight from its serial measurement. Thromb Res 148:9–14
pubmed: 27764730
doi: 10.1016/j.thromres.2016.10.011
Helin TA et al (2017) Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement. J Thromb Thrombolysis 43(4):562–569
pubmed: 28315166
doi: 10.1007/s11239-017-1492-2
Hitaka Y et al (2016) Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation. J Cardiol 68(6):529–535
pubmed: 26987789
doi: 10.1016/j.jjcc.2015.12.009
Chan MY et al (2012) Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost 108(6):1180–1191
pubmed: 23052711
doi: 10.1160/TH12-05-0310
Katoh H, Nozue T, Michishita I (2017) Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation. Heart Vessels 32(9):1130–1136
pubmed: 28283738
doi: 10.1007/s00380-017-0962-y
Kitagawa F et al (2017) Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population. Heart Vessels 32(5):609–617
pubmed: 27796530
doi: 10.1007/s00380-016-0912-0
Mani H et al (2011) Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 106(1):156–164
pubmed: 21655672
Molenaar PJ, Dinkelaar J, Leyte A (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50(10):1799–1807
pubmed: 23089710
doi: 10.1515/cclm-2012-0055
Nakano Y et al (2015) Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. J Cardiol 65(3):185–190
pubmed: 25192594
doi: 10.1016/j.jjcc.2014.07.021
Oswald E et al (2015) Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study. Blood Coagul Fibrinolysis 26(2):136–144
pubmed: 25396759
doi: 10.1097/MBC.0000000000000203
Platton S, Bowles L, MacCallum P (2017) Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents. Br J Haematol 179(3):511–513
pubmed: 27392166
doi: 10.1111/bjh.14230
Pratt J, Crispin P (2018) Screening test for direct oral anticoagulants with the dilute Russell viper venom time. Eur J Haematol 100(6):567–574
pubmed: 29486103
doi: 10.1111/ejh.13050
Steppich B et al (2017) Effect of the FXa inhibitors rivaroxaban and apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis 43(4):490–497
pubmed: 28316004
doi: 10.1007/s11239-017-1495-z
Suzuki S et al (2018) An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metab Pharmacokinet 33(4):188–193
pubmed: 29773500
doi: 10.1016/j.dmpk.2018.02.002
Tajiri K et al (2015) Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels. J Cardiol 65(3):191–196
pubmed: 25192595
doi: 10.1016/j.jjcc.2014.08.006
Wan H et al (2016) An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis 27(8):882–885
pubmed: 26757012
doi: 10.1097/MBC.0000000000000509
Vranckx P et al (2015) Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease the X-PLORER trial. Thromb Haemost 114(2):258–267
pubmed: 25925992
pmcid: 6374984
doi: 10.1160/TH15-01-0061
Douxfils J et al (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130(6):956–966
pubmed: 23006523
doi: 10.1016/j.thromres.2012.09.004
Parry TJ et al (2011) Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis 22(8):720–726
pubmed: 21986468
doi: 10.1097/MBC.0b013e32834cb30e
Rosenkranz AC, Schror K, Rauch BH (2011) Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells. Thromb Haemost 106(3):561–562
pubmed: 21800011
doi: 10.1160/TH11-04-0275
Sparkenbaugh EM et al (2014) Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123(11):1747–1756
pubmed: 24449213
pmcid: 3954055
doi: 10.1182/blood-2013-08-523936
Lim HY et al (2019) A review of global coagulation assays - Is there a role in thrombosis risk prediction? Thromb Res 179:45–55
pubmed: 31078120
doi: 10.1016/j.thromres.2019.04.033
Hirota N et al (2020) Analysis of bioMARKer distribution and individual reproducibility under rivaroxaban treatment in japanese patients with non-valvular atrial fibrillation (R-MARK Study, CVI ARO2). Int Heart J 61(4):695–704
pubmed: 32684604
doi: 10.1536/ihj.20-041
Biemond BJ et al (2007) Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)–an oral, direct factor Xa inhibitor. Thromb Haemost 97(3):471–477
pubmed: 17334516
doi: 10.1160/TH06-11-0620
Zhou W et al (2013) Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 44(3):771–778
pubmed: 23339956
doi: 10.1161/STROKEAHA.112.675231
Gosselin RC et al (2014) Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 138(12):1680–1684
pubmed: 25427046
doi: 10.5858/arpa.2013-0750-OA
Aronson DL et al (1977) Generation of the combined prothrombin activation peptide (F1–2) during the clotting of blood and plasma. J Clin Invest 60(6):1410–1418
pubmed: 410831
pmcid: 372499
doi: 10.1172/JCI108902
Ueno EI et al (2020) Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban. J Thromb Thrombolysis 50(2):371–379
pubmed: 32166540
doi: 10.1007/s11239-020-02079-7
Weisshaar S et al (2014) Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. J Thromb Haemost 12(11):1850–1860
pubmed: 25211369
doi: 10.1111/jth.12726
Brunner-Ziegler S et al (2016) Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects. J Thromb Haemost 14(2):316–323
pubmed: 26644369
doi: 10.1111/jth.13213
Liles J et al (2016) Increased level of thrombotic biomarkers in patients with atrial fibrillation despite traditional and new anticoagulant therapy. Clin Appl Thromb Hemost 22(8):743–748
pubmed: 27170781
doi: 10.1177/1076029616648407
Miyazawa K et al (2018) Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). Ann Med 50:511–518
pubmed: 29956554
doi: 10.1080/07853890.2018.1495337
Kirchhof P et al (2020) Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial. TH Open 4(1):e20–e32
pubmed: 31984306
pmcid: 6978177
doi: 10.1055/s-0040-1701206
Hoek JA et al (1988) Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 34(10):2058–2062
pubmed: 3168216
doi: 10.1093/clinchem/34.10.2058
Stepien E et al (2007) Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Med Wewn 117(7):297–305
pubmed: 17966595
Deguchi K et al (1991) Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol 38(2):86–89
pubmed: 1951313
doi: 10.1002/ajh.2830380203
Dittmeier M et al (2016) Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism. Thromb Haemost 115(4):835–843
pubmed: 26489881
doi: 10.1160/TH15-08-0631
Hara T et al (2015) Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 242(2):639–646
pubmed: 25817329
doi: 10.1016/j.atherosclerosis.2015.03.023
Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3(8):1800–1814
pubmed: 16102047
doi: 10.1111/j.1538-7836.2005.01377.x
Posma JJ et al (2019) Roles of coagulation proteases and PARs (Protease-Activated Receptors) in mouse models of inflammatory diseases. Arterioscler Thromb Vasc Biol 39(1):13–24
pubmed: 30580574
pmcid: 6310042
doi: 10.1161/ATVBAHA.118.311655
Camerer E, Huang W, Coughlin SR (2000) Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97(10):5255–5260
pubmed: 10805786
pmcid: 25815
doi: 10.1073/pnas.97.10.5255
Demetz G et al (2010) Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis 212(2):466–471
pubmed: 20708733
doi: 10.1016/j.atherosclerosis.2010.07.017
Chung CC et al (2018) Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis. J Mol Cell Cardiol 123:128–138
pubmed: 30213724
doi: 10.1016/j.yjmcc.2018.09.003
Puech C et al (2019) Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway. Brain Res 1719:57–63
pubmed: 31121158
doi: 10.1016/j.brainres.2019.05.024
Petzold T et al (2020) Rivaroxaban Reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res 126(4):486–500
pubmed: 31859592
doi: 10.1161/CIRCRESAHA.119.315099
Gaffney PJ, Joe F (1979) The lysis of crosslinked human fibrin by plasmin yields initially a single molecular complex D dimer-E. Thromb Res 15(5–6):673–687
pubmed: 158848
doi: 10.1016/0049-3848(79)90177-4
Soomro AY et al (2016) The current role and future prospects of D-dimer biomarker. Eur Heart J Cardiovasc Pharmacother 2(3):175–184
pubmed: 27533759
doi: 10.1093/ehjcvp/pvv039
AlKhalfan F et al (2018) D-Dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (an ATLAS ACS-TIMI 46 trial substudy). Am J Cardiol 122(9):1459–1464
pubmed: 30217378
doi: 10.1016/j.amjcard.2018.07.032
Scheres LJJ et al (2018) Measurement of coagulation factors during rivaroxaban and apixaban treatment: results from two crossover trials. Res Pract Thromb Haemost 2(4):689–695
pubmed: 30349888
pmcid: 6178718
doi: 10.1002/rth2.12142
Spyropoulos AC et al (2020) Modified IMPROVE VTE risk score and elevated D-dimer identify a High venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open 4(1):e59–e65
pubmed: 32190813
pmcid: 7069762
doi: 10.1055/s-0040-1705137
Ferreira JP et al (2020) Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. Eur J Heart Fail 23:648–656
pubmed: 32959502
doi: 10.1002/ejhf.2003
Estevez B et al (2016) Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood 127(5):626–636
pubmed: 26585954
pmcid: 4742550
doi: 10.1182/blood-2015-04-638387
Flierl U et al (2013) The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure. Pharmacol Res 74:49–55
pubmed: 23714416
doi: 10.1016/j.phrs.2013.05.002
Pignatelli P et al (2016) Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacol Res 113(Pt A):484–489
pubmed: 27693274
doi: 10.1016/j.phrs.2016.09.035
Ringwala SM, Dibattiste PM, Schneider DJ (2012) Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis 34(3):291–296
pubmed: 22528328
doi: 10.1007/s11239-012-0727-5
Ordi-Ros J et al (2019) Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 171(10):685–694
pubmed: 31610549
doi: 10.7326/M19-0291
Zemer-Wassercug N et al (2015) The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J Thromb Thrombolysis 40(3):340–346
pubmed: 26184605
doi: 10.1007/s11239-015-1245-z
Sower LE et al (1995) Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 155(2):895–901
pubmed: 7608566
doi: 10.4049/jimmunol.155.2.895
Chen D et al (2008) Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 205(8):1739–1746
pubmed: 18606855
pmcid: 2525584
doi: 10.1084/jem.20071427
Yang H et al (2013) Induction of tumor necrosis factor (TNF) release from subtypes of T cells by agonists of proteinase activated receptors. Mediators Inflamm 2013:165453
pubmed: 24453410
pmcid: 3876890
doi: 10.1155/2013/165453
Foley JH, Conway EM (2016) Cross talk pathways between coagulation and inflammation. Circ Res 118(9):1392–1408
pubmed: 27126649
doi: 10.1161/CIRCRESAHA.116.306853
Sanada F et al (2016) Activated factor X induces endothelial cell senescence through IGFBP-5. Sci Rep 6:35580
pubmed: 27752126
pmcid: 5067718
doi: 10.1038/srep35580
Wypasek E et al (2020) Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. Vascul Pharmacol 130:106679
pubmed: 32387621
doi: 10.1016/j.vph.2020.106679
Ellinghaus P et al (2016) Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res 142:44–51
pubmed: 27131284
doi: 10.1016/j.thromres.2016.04.008
Ishibashi Y, Matsui T, Fukami K, Ueda S, Okuda S, Yamagishi S (2015) Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system. Thromb Res 135(4):770–3
pubmed: 25636461
doi: 10.1016/j.thromres.2015.01.023
Monux G et al (2017) FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms. Br J Clin Pharmacol 83(12):2661–2670
pubmed: 28735510
pmcid: 5698591
doi: 10.1111/bcp.13383
Laurent M et al (2014) Comparative study of the effect of rivaroxaban and fondaparinux on monocyte’s coagulant activity and cytokine release. Exp Hematol Oncol 3(1):30
pubmed: 25601900
pmcid: 4298120
doi: 10.1186/2162-3619-3-30
Zhou Q et al (2011) Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011:432080
pubmed: 21772662
pmcid: 3134269
doi: 10.1155/2011/432080
Goto M et al (2016) Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol 220:602–607
pubmed: 27390997
doi: 10.1016/j.ijcard.2016.06.212
Daci A et al (2020) Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. PLoS One 15(12):e0240669
pubmed: 33301454
pmcid: 7728205
doi: 10.1371/journal.pone.0240669
Ding Y et al (2020) Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation. Vascul Pharmacol 136:106818
pubmed: 33227452
doi: 10.1016/j.vph.2020.106818
Terry CM, He Y, Cheung AK (2016) Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res 144:106–112
pubmed: 27318247
pmcid: 4980169
doi: 10.1016/j.thromres.2016.06.008
Bergmeier W, Hynes RO (2011) Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect in Biol 4(2):a005132
Gerlach RF et al (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344(1):147–149
pubmed: 15950912
doi: 10.1016/j.ab.2005.04.038
Halade GV, Jin YF, Lindsey ML (2013) Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 139(1):32–40
pubmed: 23562601
pmcid: 3660444
doi: 10.1016/j.pharmthera.2013.03.009
Maeda M, Tsuboi T, Hayashi T (2019) An inhibitor of activated blood coagulation factor x shows anti-endothelial senescence and anti-atherosclerotic effects. J Vasc Res 56(4):181–190
pubmed: 31266015
doi: 10.1159/000499975
Pistrosch F et al (2021) Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. Diabetologia 64(12):2701–2712
pubmed: 34495376
pmcid: 8563606
doi: 10.1007/s00125-021-05562-9
Conway DS et al (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43(11):2075–2082
pubmed: 15172416
doi: 10.1016/j.jacc.2003.11.062
Wu N et al (2013) Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol 169(1):62–72
pubmed: 24095158
doi: 10.1016/j.ijcard.2013.08.078
Li J et al (2010) Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 7(4):438–444
pubmed: 20153266
doi: 10.1016/j.hrthm.2009.12.009
Olson NC et al (2014) Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost 12(12):1993–2001
pubmed: 25292154
pmcid: 4643856
doi: 10.1111/jth.12742
Matos MF et al (2011) The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res 128(3):216–220
pubmed: 21620438
doi: 10.1016/j.thromres.2011.04.016
Wells PS et al (2003) Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349(13):1227–1235
pubmed: 14507948
doi: 10.1056/NEJMoa023153
Wu CT et al (2018) Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis. J Orthop Surg Res 13(1):173
pubmed: 29996862
pmcid: 6042345
doi: 10.1186/s13018-018-0883-1
Cohen AT et al (2014) D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 12(4):479–487
pubmed: 24460645
doi: 10.1111/jth.12515
Borris LC et al (2008) Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events. J Thromb Haemost 6(10):1671–1679
pubmed: 18680542
doi: 10.1111/j.1538-7836.2008.03120.x
Nymo SH et al (2014) Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail 16(1):68–75
pubmed: 23918775
doi: 10.1093/eurjhf/hft125
Martins GL et al (2020) Comparison of inflammatory mediators in patients with atrial fibrillation using warfarin or rivaroxaban. Front Cardiovasc Med 7:114
pubmed: 32793635
pmcid: 7393940
doi: 10.3389/fcvm.2020.00114
Di Lullo L et al (2021) New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation. Int J Cardiol 345:90–97
pubmed: 34688719
doi: 10.1016/j.ijcard.2021.10.025
Yang K-C, Dudley SC (2013) Oxidative stress and atrial fibrillation. Circulation 128(16):1724–1726
pubmed: 24030497
pmcid: 3909513
doi: 10.1161/CIRCULATIONAHA.113.005837
Caliskan A et al (2014) Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion. J Thromb Thrombolysis 37(4):464–468
pubmed: 24218342
doi: 10.1007/s11239-013-1019-4
Richards GA et al (2018) The effects of dabigatran and rivaroxaban on markers of polymorphonuclear leukocyte activation. Pharmaceuticals (Basel) 11(2):46
pubmed: 29758017
doi: 10.3390/ph11020046
Ichikawa H et al (2019) Rivaroxaban, a Direct factor xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc 8(8):e012195
pubmed: 30957622
pmcid: 6507187
doi: 10.1161/JAHA.119.012195
Korjian S et al (2019) Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care 8(2):186–193
pubmed: 29249166
doi: 10.1177/2048872617745003
Scheitz JF et al (2020) High-sensitivity cardiac troponin T for risk stratification in patients with embolic stroke of undetermined source. Stroke 51(8):2386–2394
pubmed: 32640945
doi: 10.1161/STROKEAHA.120.029628
Cunningham JW et al (2020) Natriuretic Peptide-based inclusion criteria in a heart failure clinical trial: insights from COMMANDER HF. JACC Heart Fail 8(5):359–368
pubmed: 32171760
doi: 10.1016/j.jchf.2019.12.009
Gue YX et al (2020) Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study : a randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. J Thromb Thrombolysis 49(2):192–198
pubmed: 31872349
doi: 10.1007/s11239-019-02014-5
Geyer PE et al (2017) Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13(9):942
pubmed: 28951502
pmcid: 5615924
doi: 10.15252/msb.20156297
Hathout Y (2015) Proteomic methods for biomarker discovery and validation. Are we there yet? Expert Rev Proteomics 12(4):329–31
pubmed: 26186709
doi: 10.1586/14789450.2015.1064771
Kirchhof P et al (2007) Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9(11):1006–1023
pubmed: 17897925
doi: 10.1093/europace/eum191
Ko D et al (2019) Proteomics profiling and risk of new-onset atrial fibrillation: framingham heart study. J Am Heart Assoc 8(6):e010976–e010976
pubmed: 30841775
pmcid: 6475036
doi: 10.1161/JAHA.118.010976
Wells QS et al (2019) Accelerating biomarker discovery through electronic health records, automated biobanking, and proteomics. J Am Coll Cardiol 73(17):2195–2205
pubmed: 31047008
pmcid: 6501811
doi: 10.1016/j.jacc.2019.01.074
Tantry U et al (2020) Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. Future Cardiol 16(2):69–75
pubmed: 32129681
doi: 10.2217/fca-2019-0091
Riley RS et al (2016) Widely used types and clinical applications of D-dimer assay. Lab Med 47(2):90–102
pubmed: 27016528
doi: 10.1093/labmed/lmw001
Thachil J, Lippi G, Favaloro EJ (2017) D-dimer testing: laboratory aspects and current issues. Methods Mol Biol 1646:91–104
pubmed: 28804821
doi: 10.1007/978-1-4939-7196-1_7